Understanding cardiac amyloidosis in heart failure with preserved ejection fraction
Cardiac Amyloidosis in Heart Failure Patients With Preserved Ejection Fraction
This study is trying to find out how common a specific type of amyloidosis is in older patients with heart failure that has preserved ejection fraction, to help improve how we diagnose and treat this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04587648 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the underlying causes of heart failure with preserved ejection fraction (HFpEF), particularly focusing on the role of cardiac amyloidosis. It will involve patients aged 60 and older, or those aged 50 with specific conditions, who have been diagnosed with HFpEF. The study will assess the prevalence of wild-type transthyretin amyloidosis among these patients using diagnostic methods such as scintigraphy. By identifying the presence of amyloid deposits, the study hopes to improve diagnosis and treatment strategies for HFpEF.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 60 and older, or those aged 50 with carpal tunnel syndrome or spinal stenosis, who have been diagnosed with HFpEF.
Not a fit: Patients with unstable coronary artery disease or a history of heart failure with reduced ejection fraction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnosis and targeted treatments for patients suffering from HFpEF caused by cardiac amyloidosis.
How similar studies have performed: While studies on cardiac amyloidosis exist, the specific focus on its prevalence in HFpEF patients is less explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient is ≥ 60 years old or 50 y/o with carpal tunnel syndrome or spinal stenosis * Patient has been diagnosed as HFpEF in their medical history or newly diagnosed as HFpEF. They have HF symptoms with NYHA Classification of I-IV when diagnosis. The criteria of HFpEF is according to our previous studies. * More than 50% of them have LVPW ≥12mm (when diagnosis). * Written informed consent could be obtained. Exclusion Criteria: * Patients unwilling to join this projects. * Patients with unstable coronary artery disease, plan to receive coronary intervention within months. * Patients has previous history of HFrEF with a LVEF \<40%.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.